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Introduction
Host inflammatory and immune
responses to specific oral bacterial
infections can result in periodontal
disease, i.e., periodontitis (1). Human
periodontitis is heterogeneous in eti-
ology, but a common hallmark is alve-
olar bone destruction, one of the
major causes of tooth loss in human
(2, 3). Interestingly, human periodon-
titis has recently been implicated in
the increased risks of certain systemic
disorders such as pre-term low birth
weight, bacterial pneumonia, conges-
tive heart diseases, and stroke (4–8),
possibly due to an underlying inflam-
matory trait (9). About 10–12 subgin-
gival microorganisms have been impli-
cated in the pathogenesis of
periodontitis, including Porphyromonas
gingivalis, Prevotella intermedia, Bac-
teroides forsythus, and mixed spirochetes
(10). In particular, Actinobacillus actino-
mycetemcomitans, a Gram-negative fac-
ultative capnophilic rod bacterium,
has been identified as the etiological
agent of localized juvenile periodonti-
tis (LJP) and of some rapidly progress-
ing and severe forms of periodontitis
(10–13). The prevalence of LJP is about
1–4% among teens and young adults,
and 10% among insulin-dependent
diabetic patients (10). LJP is character-
ized by advanced alveolar bone
destruction in a molar-incisor pattern
that often leads to tooth mobility and
loss, resulting in functional and aes-
thetic deficits.
A. actinomycetemcomitans is able to
invade the gingival epithelium (14)
and releases several virulence factors
such as cytotoxins, endotoxins, and a
potent leukotoxin (15–17). A. actino-
mycetemcomitans infection is usually
accompanied by local and systemic
antigen-specific immune responses
(18–19). Earlier studies demonstrated
altered CD4+/CD8+ T-cell ratios and
autologous mixed lymphocyte reac-
tions in LJP patients (20, 21) and the
ability of T helper cells to home to
periodontal tissues in rat and mouse
models of periodontitis (22–24). Fur-
ther, we have previously demonstrat-
ed that A. actinomycetemcomitans infec-
tion in NOD/SCID mice engrafted
with human peripheral blood leuko-
cytes (HuPBLs) leads to periodontal
inflammation characterized by the
infiltration of CD4+ T cells, CD8+ T
cells, CD20+ B cells, and Mac1+
macrophages into the fibrous connec-
tive tissues adjacent to the periodon-
tal pockets (24). These results sug-
gested that T cells could modulate
bacterium-induced periodontal
inflammation and/or alveolar bone
destruction. However, the exact role of
T-cell subtypes and B cells in peri-
odontitis, the role of antibacterial
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Periodontitis, a prime cause of tooth loss in humans, is implicated in the
increased risk of systemic diseases such as heart failure, stroke, and bacterial
pneumonia. The mechanisms by which periodontitis and antibacterial immu-
nity lead to alveolar bone and tooth loss are poorly understood. To study the
human immune response to specific periodontal infections, we transplanted
human peripheral blood lymphocytes (HuPBLs) from periodontitis patients
into NOD/SCID mice. Oral challenge of HuPBL-NOD/SCID mice with Acti-
nobacillus actinomycetemcomitans, a well-known Gram-negative anaerobic
microorganism that causes human periodontitis, activates human CD4+ T cells
in the periodontium and triggers local alveolar bone destruction. Human CD4+
T cells, but not CD8+ T cells or B cells, are identified as essential mediators of
alveolar bone destruction. Stimulation of CD4+ T cells by A. actinomycetemcomi-
tans induces production of osteoprotegerin ligand (OPG-L), a key modulator of
osteoclastogenesis and osteoclast activation. In vivo inhibition of OPG-L func-
tion with the decoy receptor OPG diminishes alveolar bone destruction and
reduces the number of periodontal osteoclasts after microbial challenge. These
data imply that the molecular explanation for alveolar bone destruction
observed in periodontal infections is mediated by microorganism-triggered
induction of OPG-L expression on CD4+ T cells and the consequent activation
of osteoclasts. Inhibition of OPG-L may thus have therapeutic value to prevent
alveolar bone and/or tooth loss in human periodontitis.
This article may have been published online in advance of the print edition. The date of public-
ation is available from the JCI website, http://www.jci.org. J. Clin. Invest. 106:R59–R67 (2000).
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immunity in local alveolar bone
destruction, and the mechanisms by
which host immune responses con-
tribute to alveolar bone destruction
and/or tooth loss remain unclear.
To investigate the mechanism or
mechanisms that regulate periodontal
immunity and alveolar bone destruc-
tion, we transplanted HuPBLs from
LJP patients into NOD/SCID mice
(which lack endogenous T and B cells),
generating HuPBL-NOD/SCID mice
(24). Here we show that oral challenge
of these “humanized” mice with A.
actinomycetemcomitans (designated Aa-
HuPBL-NOD/SCID) leads to func-
tional activation of the human CD4+ T
cells in the periodontium and triggers
local alveolar bone destruction. In
vitro stimulation of CD4+ T cells from
these mice with antigens from A. actin-
omycetemcomitans leads to the expres-
sion of osteoprotegerin ligand (OPG-
L, also known as TRANCE, ODF, and
RANKL), a key mediator of osteoclas-
togenesis and osteoclast activation
(25–31). Inhibition of OPG-L function
via the decoy receptor osteoprotegerin
(OPG) significantly reduces the alveo-
lar bone destruction detected in Aa-
HuPBL-NOD/SCID mice after bacter-
ial inoculation, as well as the numbers
of osteoclasts at the sites of local peri-
odontal inflammation. These results
identify for the first time a critical role
for human CD4+ T cells reactive to oral
microorganisms in periodontal dis-
ease. Moreover, A. actinomycetemcomi-
tans–triggered induction of OPG-L
expression on T cells and OPG-
L–mediated osteoclast activation and
bone loss could provide one molecular
explanation for the alveolar bone
destruction observed in local peri-
odontal infection.
Methods
Patients. Four LJP patients (3 males
and 1 female, mean age 21 ± 4.4 years)
were recruited as blood donors for the
current study. Inclusion criteria, as
defined previously (24), were: (a) pos-
itive anti–A. actinomycetemcomitans
immunofluorescence reactions of
subgingival plaque samples collected
adjacent to advanced lesions, and (b)
high serum Ab titers to A. actino-
mycetemcomitans (Y-4 or JP2 strains;
see below) as detected by ELISA. Age-
matched healthy subjects without
clinical evidence of periodontal dis-
ease were recruited as controls.
Informed consent was obtained from
the patients, and all protocols used
were approved by the Human Ethics
Committee and the Animal Experi-
mentation Committee of the Univer-
sity of Western Ontario.
Reagents. The following reagents were
commercially purchased: Ficoll-
Hypaque (Pharmacia Biotech Inc., Pis-
cataway, New Jersey, USA); collagenase
(Sigma Chemical Co., St. Louis, Mis-
souri, USA); mAb’s specific for human
CD45+ hematopoietic cells, human
CD45RO+ T cells, and human CD19+
pan-B cells (Serotec Ltd., Kidlington,
Oxford, United Kingdom); anti-
human T-cell receptor (TCR- a b ),
CD25, CD28, Fc receptor, CD3, CD4,
CD8, and CD14 mAb’s (PharMingen,
San Diego, California, USA); rabbit
and human complements (Cedarlane
Laboratories Ltd., Hornby, Ontario,
Canada); goat anti-mouse and mouse
anti-human IgG-H+L FITC-conjugat-
ed Ab’s (Bio-Rad Laboratories Inc.,
Hercules, California, USA, and R&D
Systems Inc., Minneapolis, Minnesota,
USA, respectively); and isotypic con-
trol Ab’s (Sigma Chemical Co.;
PharMingen). Human recombinant
OPG-FITC conjugate and OPG-Fc
fusion protein were prepared as previ-
ously described (25–27, 31). All tissue
culture was performed in complete
RPMI 1640 medium supplemented
with 2–3% individual donor’s serum
and 10% FCS (GIBCO BRL, Burling-
ton, Ontario, Canada).
Generation of HuPBL-NOD/SCID mice
and A. actinomycetemcomitans inocula-
tion. At day 0, 8- to 9-week-old female
NOD/SCID (H2d/d) mice were subject-
ed to 2.5 Gy g -irradiation prior to
intraperitoneal injection of 10 · 106 to
35 · 106 mononuclear cells freshly pre-
pared from HuPBLs by Ficoll-
Hypaque gradient centrifugation (24,
32–33). On days 1, 3, and 5, the
HuPBL-NOD/SCID mice were inocu-
lated orally with live A. actinomycetem-
comitans (100 m l of 1010 CFU/ml cul-
ture broth grown in an anaerobic
chamber; Y-4 strain [no. 43781, Amer-
ican Type Culture Collection,
Rockville, Maryland, USA] or JP2
strain [no. 29523, American Type Cul-
ture Collection]). Autologous HuPBL
engraftment (weekly) and bacterial
challenge (3 times per week) were
repeated for 3–4 consecutive weeks.
The infected mice were designated Aa-
HuPBL-NOD/SCID mice. All Aa-
HuPBL-NOD/SCID mice had serum
levels of 0.1–0.85mg/ml IgG Ab’s
against A. actinomycetemcomitans. All
mice were housed under specific
pathogen-free conditions at the Ani-
mal Facility of the Faculty of Medicine
and Dentistry, the University of West-
ern Ontario, following institutional
guidelines.
Measurement of alveolar bone loss in
mice. Changes in alveolar bone mass in
Aa-HuPBL-NOD/SCID mice were
determined in maxillary molars as
described (34). Briefly, horizontal
bone loss, the distance between the
cementum-enamel junction (CEJ) and
the alveolar bone crest (ABC) along
the long axis of either the buccal or
lingual roots, was measured under a
dissecting microscope on the
mesiobuccal, midbuccal, distobuccal,
mesiolingual, midlingual, and dis-
tolingual sites of the maxillary right
and left molars (M1 and M2). The
mean horizontal bone loss in each
experimental group was calculated
from the pooled data sets (the meas-
urements of individual right and left
molars, M1 and M2, per mouse). Base-
line alveolar bone height was meas-
ured at day 1 (start point), whereas
values at the fourth and eighth week
were recorded as mid- and end-points,
respectively. Results for each experi-
mental group were normalized to the
mean alveolar bone loss in control A.
actinomycetemcomitans–inoculated
BALB/c (H2d/d) mice (100% » 0.6 ±
0.12 mm per tooth in an 8-week peri-
od). Statistical significance of differ-
ences in alveolar bone loss between
different groups was assessed by one-
way ANOVA with a P value of less
than 0.05.
T-cell activation. Periodontal CD4+ T
cells were prepared from Aa-HuPBL-
NOD/SCID mice during weeks 4–6
and restimulated in 24-well plates with
100 m g/ml antigens from sonicated A.
actinomycetemcomitans antigens (24) in
the presence of irradiated (25 Gy)
autologous HuPBL-derived mono-
cytes/macrophages as antigen-pre-
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senting cells (APCs) (24). After 48
hours, T-cell blasts were collected by
Ficoll gradient centrifugation and
sequentially immunostained with
anti-human CD25 (IL-2 receptor- a
chain) and FITC-conjugated goat anti-
mouse IgG (H+L) Ab. The positive
controls included human Jurkat T
cells and HuPBL-derived CD4+ T cells
whose TCRs were cross-linked with
anti-human TCR mAb (10 m g/ml for
106 cells) and anti–Fc receptor mAb.
After 24 hours, 3 · 105 to 4 · 105 cells
per sample were washed and CD25
expression was determined by flow
cytometric analysis using a FACScan. 
Immunization with A. actinomycetem-
comitans in vivo. Systemic immune
responses to A. actinomycetemcomitans
were tested 6 weeks after the start of
the experiment. Aa-HuPBL-
NOD/SCID mice were immunized
intraperitoneally with 30 m l A. actino-
mycetemcomitans sonicate antigens (1
m g/ m l) mixed 1:1 with a 1:10 mixture
of CFA/IFA adjuvants. After 14 days,
human CD4+ T cells were isolated
from mouse spleens and purified by
FACS (purity >85–95%). Purified T
cells were subjected in triplicate to in
vitro stimulation (1.5 · 104 T
cells/well in U-bottom 96-well plates)
using serial dilutions of A. actino-
mycetemcomitans sonicate antigens
(1–100 m g/ml). After 48 hours, super-
natants were collected for analysis of
human IL-2 production by bioassay
with IL-2–dependent CTLL-2 cells as
described (24, 35). Periodontal CD4+
T cells from Aa-HuPBL-NOD/SCID
mice served as positive controls, while
splenic CD4+ T cells from nonimmu-
nized HuPBL-NOD/SCID mice con-
stituted the negative control.
Lymphocyte depletion and adoptive trans-
fer experiments. For in vivo depletion of
human lymphocytes in HuPBL-
NOD/SCID mice, mAb’s specific for
human CD4+ T cells, CD8+ T cells, or B
cells were injected (150–200 m g)
intraperitoneally every 5–7 days from
weeks 4–8 in the presence of human
complement (24, 32–33). PBLs and
splenocytes were stained with phyco-
erythrin-conjugated mAb’s to human
CD4, CD8, and CD20 (pan-B cells) to
confirm the depletion of the corre-
sponding cells by FACS analysis. The
efficiency of immunodepletion was
typically 95–98% without significant
numbers of target cells remaining (data
not shown) (24, 32–33). For adoptive
transfer, 1 · 106 to 2 · 106 A. actino-
mycetemcomitans–reactive periodontal
CD4+ T cells were harvested from the
margins of oral mucosal tissues of Aa-
HuPBL-NOD/SCID mice during week
6–8; then these CD4+ T cells (1 · 106 to
2 · 106) plus 3 · 106 to 5 · 106 irradiat-
ed (25 Gy) autologous HuPBL-derived
monocytes/macrophages (as APCs)
were adoptively transferred intra-
venously into naive NOD/SCID hosts.
Adoptive transfer was performed week-
ly for 3–4 consecutive weeks and in
each case immediately followed by oral
inoculation with A. actinomycetemcomi-
tans as described above.
OPG-L expression and inhibition of OPG-
L activity in vivo. To detect OPG-L
expression, periodontal CD4+ T cells
isolated from control or Aa-HuPBL-
NOD/SCID mice were restimulated in
vitro with A. actinomycetemcomitans
sonicate antigens. OPG-L surface
expression was detected using OPG-
FITC (31). To investigate the in vivo
inhibition of OPG-L by its natural
decoy receptor OPG, recombinant
human OPG-Fc fusion protein was
injected into mice as described previ-
ously (25–27, 31). Briefly, Aa-HuPBL-
NOD/SCID and control mice were
treated intraperitoneally every other
day with PBS or OPG-Fc (1 mg/kg)
between weeks 4 and 8 for a total of 14
injections per mouse. By the end of the
8th week, all mice were sacrificed, and
then alveolar bone loss was deter-
mined as described above and assessed
by histology. Osteoclasts were identi-
fied in situ using tissue sections with
osteoclast-specific tartrate-resistant
acid phosphatase (TRAP) staining for
determining the numbers of positive
cells as described previously (31, 36).
Results
Construction of a model for A. actino-
mycetemcomitans–induced periodontal
infection in HuPBL-NOD/SCID mice. To
study the mechanism or mechanisms
that regulate periodontal immunity
and alveolar bone destruction, we
transplanted HuPBL into NOD/SCID
mice to generate HuPBL-NOD/SCID
mice by using HuPBL from LJP
patients and healthy donors, respec-
tively (24). Four independent HuPBL-
NOD/SCID chimeric mouse strains
were generated using cells from four
LJP patients. In all experiments,
screening for the human CD45+
hematopoietic cell marker revealed
that the level of HuPBL engraftment
in NOD/SCID mice detected over the
8-week period was 30–60% (24) (data
not shown). Oral inoculation of
HuPBL-NOD/SCID mice with A.
actinomycetemcomitans resulted in peri-
odontal inflammation characterized
by the infiltration of human CD4+ T
cells, CD8+ T cells, CD20+ B cells, and
Mac1+ macrophages into the fibrous
connective tissues adjacent to the peri-
odontal pockets at the site of infec-
tion (24). Further, we have recently
demonstrated the feasibility of gener-
ating human primary and secondary
immune responses to exogenous anti-
gens and putative pathogens isolated
from human periodontal lesions in
HuPBL-SCID and HuPBL-
NOD/SCID animal models (32–33).
As a result, both periodontal and
splenic CD4+ T cells from Aa-HuPBL-
NOD/SCID mice were fully immuno-
competent, as assessed by their signif-
icant upregulation of the high-affinity
IL-2 receptor- a chain expression
(CD25; data not shown) and produc-
tion of the T-cell growth factor IL-2
(Figure 1a) in response to in vitro res-
timulation with sonicate antigens of
A. actinomycetemcomitans, respectively.
Splenic CD4+ T cells from Aa-HuPBL-
NOD/SCID mice failed to produce IL-
2 in response to restimulation in vitro
with sonicate antigens of P. gingivalis
(Figure 1a). In addition, the TCR-V a
and TCR-V b repertoire of A. actino-
mycetemcomitans–reactive CD4+ T cells
from Aa-HuPBL-NOD/SCID mice
significantly overlapped (>83%) that
of cells isolated from periodontal sur-
gical excisions from clinical LJP
patients (data not shown). These
results indicate that bacterial antigens
can activate human T cells present in
the periodontal tissues of the chimeric
mice. Thus, Aa-HuPBL-NOD/SCID
chimeric mice constitute a useful and
specific model to investigate human
oral pathogen-induced periodontal
infection.
In humans, periodontal inflamma-
tion/infection results in destruction of
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alveolar bone structure surrounding
the teeth, ultimately followed by tooth
loss (1–3). Thus, we analyzed whether
alveolar bone loss occurs in A. actino-
mycetemcomitans–infected HuPBL-
NOD/SCID mice. The results showed
that periodontal and alveolar bone
structures were comparable among
sham-infected NOD/SCID (Figure 1b,
group I) and HuPBL-NOD/SCID (Fig-
ure 1b, group II) mice, indicating that
the transfer of HuPBL per se did not
lead to tissue loss (see Figure 3a) (24).
Neither did repeated inoculation of
bacteria into nonchimeric NOD/SCID
(H2d/d) mice lead to significant levels
of alveolar bone loss (Figure 1b, group
III) compared with the positive con-
trol, A. actinomycetemcomitans–infected
BALB/c mice (total bone loss was
taken as “100%”). This is consistent
with the findings of Baker et al. (37)
that pathogen-induced alveolar bone
loss in SCID mice is significantly less
than that in immunocompetent hosts.
By week 8, groups I, II, and III
showed significantly less alveolar bone
loss (P < 0.01) than the positive control
A. actinomycetemcomitans–infected
BALB/c mice (taken as 100%), and
about the same amount as occurred in
noninfected BALB/c mice (data not
shown). This background level of
spontaneous alveolar bone loss (mean
= 22.6 ± 3.4% of the positive control;
see Figures 1b, 2, and 4e) has been
shown to occur even under normal cir-
cumstances without bacterial infec-
tion. Accordingly, it has been recog-
nized to represent a physiological
alteration of the periodontium (38).
However, oral inoculation of A. actino-
mycetemcomitans in NOD/SCID mice
reconstituted with HuPBL from LPJ
patients (Figure 1b, group IV) led, in
time, to the development of alveolar
bone destruction (mean = 82.2% of the
positive control; see Figure 3, b and c).
Chimeric mice constructed using
HuPBL from each of four different LJP
patients showed equivalent levels of
alveolar bone destruction induced by
A. actinomycetemcomitans (24) (data not
shown). In contrast, NOD/SCID
chimeric mice reconstituted with
HuPBL from healthy human donors
(Figure 1b, group V) followed by inoc-
ulation with bacteria developed only
background levels of alveolar bone
destruction by 8 weeks. These data
indicate that a model of A. actino-
mycetemcomitans–specific periodontal
infection can be produced in “human-
ized” NOD/SCID mice transplanted
with HuPBL from LJP, but not from
normal healthy subjects.
Human CD4+ T cells mediate alveolar
bone destruction in periodontitis. We used
our “humanized” mouse model to
elucidate the exact role of human T-
cell subtypes and B cells in periodon-
titis and the role of antibacterial
immunity in local alveolar bone
destruction. To assess the contribu-
tion of different lymphocyte subsets
to alveolar bone destruction, we stud-
ied the effect of immunodepletion of
CD4+ T cells, CD8+ T cells, or B cells
from Aa-HuPBL-NOD/SCID mice.
Aa-HuPBL-NOD/SCID mice depleted
of CD4+ T cells showed significantly
less alveolar bone destruction by the
end of 8 weeks (Figure 2, group III:
mean = 37.6% of the positive control)
compared with nondepleted Aa-
HuPBL-NOD/SCID mice (Figure 2,
group II). The relative reduction of
alveolar bone destruction (Figure 2,
group III) was significant (» 73.6% of
that of Aa-HuPBL-NOD/SCID mice)
after taking into account the back-
ground levels of spontaneous bone
loss (» 22.6%; P ≤ 0.005). The failure to
achieve higher levels of reduction of
alveolar bone loss was not due to
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Figure 1
(a) Immunocompetence of CD4+ T cells in Aa-HuPBL-NOD/SCID mice. IL-2 production
of periodontal CD4+ T cells (Perio-CD4/T-cells) and splenic CD4+ T cells (Aa-splenic
CD4/T-cells) isolated from A. actinomycetemcomitans–immunized HuPBL-NOD/SCID mice
is shown. Irradiated (25 Gy) HuPBL-derived autologous monocytes/macrophages (irr-PBL)
and CD4+ T cells isolated from non–Aa-immunized HuPBL-NOD/SCID mice (no Aa-splenic
CD4/T-cells) were included as the negative controls. Restimulation of Aa-immunized
splenic CD4+ T cells with a third-party antigen, P. gingivalis sonicate antigens served as the
specificity control (P.g.). Serial dilution of Aa sonicate antigens did not result in signifi-
cantly different patterns of the IL-2 responses measured. Differences in IL-2 production
between the Perio-CD4/T-cell and Aa-splenic CD4/T-cell groups as compared with the irr-
PBL, no Aa-splenic CD4/T-cell, and P.g. groups were statistically significant (P < 0.008,
paired t test). Values shown are mean IL-2 production of triplicate samples ± SD. One result
representative of three independent experiments is shown. (b) Increased alveolar bone loss
in Aa-HuPBL-NOD/SCID mice. Groups of mice as indicated were either sham-infected or
inoculated with A. actinomycetemcomitans (Aa). Data shown are the relative amounts of alve-
olar bone loss at the day of the first Aa inoculation (Day 1), by the end of 4 weeks (4th
wk), and by the end of 8 weeks (8th wk), expressed as a percentage of the amount of bone
loss in the positive control, Aa-infected BALB/c mice (100% = 0.6 – 0.12 mm per tooth in
8 weeks). Group I, sham-infected NOD/SCID mice (n = 10); group II, sham-infected
chimeric NOD/SCID mice engrafted with HuPBL from four LJP patients (n = 12); group III,
NOD/SCID mice infected with Aa (n = 16); group IV, Aa-infected chimeric NOD/SCID mice
engrafted with HuPBL from four LJP patients (n = 32); group V, Aa-infected chimeric
NOD/SCID mice engrafted with HuPBL (N-HuPBL) from two healthy donors (n = 12).
Data shown are mean values ± SD pooled from four independent experiments involving
HuPBL engraftment from four LJP subjects, each of which gave comparable results. Alve-
olar bone loss was determined as described in Methods. AThe extent of bone loss in group
IV at 8 weeks was significantly increased as compared with all other groups (P < 0.01).
incomplete depletion of CD4+ T cells,
as the efficiency of immunodepletion
was typically 95–98% by FACS analysis
(24, 32, 33). One conclusion would be
that there are other cell type(s)
involved in alveolar bone loss. Howev-
er, histopathologically, only a mild
inflammatory infiltrate was observed
in the fibrous connective tissue adja-
cent to the periodontal pockets in
seven of ten depleted mice studied
(compare Figure 3, b and c, with Fig-
ure 3d). Alveolar bone loss in sham-
infected CD4+ T cell–depleted
HuPBL-NOD/SCID mice (Figure 2,
group IV) was not significantly differ-
ent from that in the sham-infected,
nondepleted NOD/SCID mice (Figure
2, group I). By the end of 8 weeks,
depletion of CD8+ T cells (Figure 2,
group V) or B cells (Figure 2, group VI)
from Aa-HuPBL-NOD/SCID mice
did not significantly reduce alveolar
bone loss (P > 0.05) compared with
nondepleted Aa-HuPBL-NOD/SCID
mice (Figure 2; Figure 3, e and f).
Injection of either human comple-
ment alone or isotypic (IgG1a) control
Ab into Aa-HuPBL-NOD/SCID mice
resulted in the same level of alveolar
bone loss as in nondepleted Aa-
HuPBL-NOD/SCID mice (data not
shown). These data show that specific
removal of CD4+ T cells prevents
inflammation and periodontal tissue
damage in “humanized” animals in
response to oral microbial infection, a
result consistent with data from Baker
et al., who reported that P.
gingivalis–induced alveolar bone loss in
mice required CD4+ T cells (39).
To obtain direct evidence that CD4+
T cells reactive to a specific microor-
ganism can contribute to alveolar
bone destruction, we performed adop-
tive transfer experiments using puri-
fied periodontal CD4+ T cells isolated
from Aa-HuPBL-NOD/SCID mice.
Purified periodontal CD4+ T cells (1 ·
106 to 2 · 106 per mouse) were adop-
tively transferred to naive NOD/SCID
hosts in the presence of irradiated
autologous monocytes/macrophages
followed by oral inoculation with A.
actinomycetemcomitans. Transfer of
these CD4+ T cells triggered significant
alveolar bone destruction in the adop-
tive recipients by the end of 8 weeks
(Figure 2, group VII: AT-CD4T), com-
parable with that observed in nonde-
pleted Aa-HuPBL-NOD/SCID mice
(Figure 2, group II). Adoptive transfer
of irradiated autologous mono-
cytes/macrophages alone as APCs did
not yield any significant alveolar bone
loss (Figure 2, group VIII: irr-APC).
Thus, periodontal CD4+ T cells and/or
CD4+ T cell–regulated immunity are
critical for the pathogenesis of A. actin-
omycetemcomitans–induced periodontal
disease and alveolar bone destruction
in vivo (see also ref. 39).
A. actinomycetemcomitans stimulation
triggers OPG-L expression on human CD4+
T cells. It remains unclear how CD4+ T
cells mediate alveolar bone destruc-
tion in periodontal disease. We have
previously shown that T cells stimu-
lated via cross-linking of their antigen
receptors express a membrane-bound
form of OPG-L, a molecule of the
TNF receptor superfamily (25–29).
OPG-L is a key regulator of the devel-
opment and activation of osteoclasts
(26–30). Loss of OPG-L expression in
gene-targeted mice results in severe
osteopetrosis and a defect in tooth
eruption due to a complete loss of
osteoclast development (27). Further,
we have recently shown that activated
T cells can regulate systemic and local
bone loss and joint destruction in a
rat model of adjuvant-induced arthri-
tis via OPG-L expression (31). These
results prompted us to investigate the
role of OPG-L in alveolar bone
destruction during periodontal infec-
tions using our animal model.
To test whether CD4+ T cells activat-
ed by challenge with an oral microor-
ganism expressed OPG-L, CD4+ T
cells from Aa-HuPBL-NOD/SCID
mice were collected and subjected to
in vitro restimulation with A. actino-
mycetemcomitans sonicate antigens for
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Figure 2
Regulation of alveolar bone destruction by A. actinomycetemcomitans–reactive CD4+ T cells.
Groups of mice as indicated were either left untreated or inoculated with A. actinomycetem-
comitans. CD4+ T, CD8+ T, or B cells were depleted from mice using specific Ab’s and human
complement as described in Methods. Data shown are the relative amounts (± SD) of alve-
olar bone loss accumulated by the end of 8 weeks, expressed as a percentage of the bone loss
in the positive control, Aa-infected BALB/c mice (100%). Group I, sham-infected, nonde-
pleted NOD/SCID mice (n = 10); group II, Aa-infected, nondepleted HuPBL-NOD/SCID mice
(n = 32); group III, Aa-infected, CD4+ T cell–depleted NOD/SCID mice (n = 20); group IV,
sham-infected, CD4+ T cell–depleted NOD/SCID mice (n = 9); group V, Aa-infected, CD8+ T
cell–depleted NOD/SCID mice (n = 12); group VI, Aa-infected, B cell–depleted NOD/SCID
mice (n = 16); group VII, Aa-infected NOD/SCID mice bearing adoptively transferred Aa-reac-
tive CD4+ T cells (AT-CD4T) plus irradiated autologous monocytes/macrophages as APCs
(n = 10); group VIII, Aa-infected NOD/SCID mice bearing adoptively transferred irradiated
autologous monocytes/macrophages as APCs (irr-APC; n = 6). AStatistically significant dif-
ference in bone loss between group III and groups II, IV, V, and VI (P < 0.005).
2 days, followed by FACS analysis.
Our data indicated that microbial
stimulation did induce OPG-L expres-
sion on the surface of CD4+ T cells
(Figure 4, a–d). Interestingly, CD4+ T
cells from Aa-HuPBL-NOD/SCID
mice failed to produce OPG-L in
response to restimulation in vitro
with a third-party species, P. gingivalis
sonicate antigens (see Figure 4 leg-
end), indicating that OPG-L induc-
tion is antigen-specific. Moreover,
using RT-PCR we observed OPG-L
mRNA expression in CD4+ T cells iso-
lated from the periodontal tissues of
Aa-HuPBL-NOD/SCID and human
LJP patients (data not shown). To
determine whether the elevated
expression of OPG-L correlated with
an increase in osteoclast numbers, we
determined the numbers of osteo-
clasts in the alveolar crestal bone areas
of molars using TRAP staining, an
enzymatic staining that specifically
identifies osteoclast lineage cells (31,
36). Whereas only a few TRAP+ osteo-
clasts were detected in noninfected
HuPBL-NOD/SCID mice (used as a
negative control), osteoclast numbers
were significantly increased in Aa-
HuPBL-NOD/SCID mice (Table 1).
Thus, microbial stimulation of
human CD4+ T cells triggers the pro-
duction of the key osteoclast activa-
tion and differentiation factor OPG-
L, and local microbial infections
increase the numbers of osteoclasts in
the periodontal tissues. These data
provide the first direct evidence, to
our knowledge, that environmental
pathogens, i.e., the oral microorgan-
ism A. actinomycetemcomitans, can acti-
vate OPG-L production in T cells.
Inhibition of OPG-L in vivo blocks alveo-
lar bone destruction in A. actinomycetem-
comitans–inoculated “humanized” mice.
To test whether OPG-L expression has
biological relevance in alveolar bone
destruction during periodontal infec-
tions, that is, whether the inhibition of
OPG-L activity in vivo could reduce A.
actinomycetemcomitans–induced alveo-
lar bone loss, we took advantage of the
existence of OPG, the natural decoy
receptor of OPG-L (26–27, 31). Soluble
recombinant OPG-Fc fusion protein
was injected intraperitoneally into Aa-
HuPBL-NOD/SCID mice every other
day for 4 weeks. By the end of 8 weeks,
the amount of alveolar bone loss
detected in OPG-Fc–treated Aa-
HuPBL-NOD/SCID mice was signifi-
cantly reduced (Figure 3, g and h; Fig-
ure 4e, group III: mean = 38.2% of the
positive control) compared with that
of Aa-HuPBL-NOD/SCID mice that
were not injected with OPG-Fc (Figure
4e: group II). This reduction of alveo-
lar bone destruction (Figure 4e, group
III) was significant (» 72.6% of that of
Aa-HuPBL-NOD/SCID mice) after
taking account of the background lev-
els of spontaneous bone loss. Control
injection of PBS, the vehicle for OPG-
Fc, into Aa-HuPBL-NOD/SCID mice
(Figure 4e, group IV) did not signifi-
cantly alter alveolar bone loss when
compared with group II. In a separate
experiment, injecting ten times the
amount of OPG-Fc in vivo (n = 4) did
not result in any further reduction of
alveolar bone destruction (data not
shown), suggesting that (a) maximal
dose inhibition was attained, and/or
(b) another cell type or types may be
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Figure 3
Histopathological lesions and bone loss in Aa-HuPBL-NOD/SCID mice. CEJ, cemento-
enamel junction, a landmark for tissue loss; ABC, alveolar bone crest. The distance
between CEJ and ABC reflects the amount of tissue or alveolar bone loss measured as
described in Methods. (a) A representative tissue section from sham-infected HuPBL-
NOD/SCID mice demonstrating the normal periodontal and alveolar bone structures (as
in Figure 1b, group II). (b, c) Typical histopathological lesions show significant inflam-
matory infiltration, connective tissue loss below CEJ (in b), and alveolar bone loss with
apical growth of sulcular epithelium below CEJ and into alveolar bone area (in c) in Aa-
HuPBL-NOD/SCID mice (as in Figure 2, group II) by the end of 8 weeks. Some multinu-
cleated giant cells (arrows in c) can be observed along the surface of alveolar crestal bone.
(d) Mild inflammatory infiltrates without obvious alveolar bone loss, as evidenced by sul-
cular epithelium located at CEJ, in the periodontal tissues of CD4+ T cell–depleted Aa-
HuPBL-NOD/SCID mice (as in Figure 2, group III) by the end of 8 weeks. (e, f) In vivo
depletion of CD8+ T cells (e) (as in Figure 2, group V) or B cells (f) (as in Figure 2, group
VI) has no apparent effects on existing periodontal inflammation accompanied by tissue
loss below CEJ (in e) or alveolar bone loss with apical growth of sulcular epithelium below
CEJ and ABC (in f). These findings are consistent with those observed in nondepleted Aa-
HuPBL-NOD/SCID mice in b and c. (g, h) In vivo inhibition of OPG-L via the decoy recep-
tor OPG abrogates alveolar bone destruction, as evidenced by sulcular epithelium located
at CEJ and above ABC (in both panels), in Aa-HuPBL-NOD/SCID mice by the end of 8
weeks (as in Figure 4e, group III). Note that OPG treatment does not affect periodontal
inflammation observed in g and h. Aa-infected HuPBL-NOD/SCID mice were treated with
an OPG-Fc fusion protein as described in Methods. Parts g and h are representative of
eight mice studied in this group. Magnifications: a, b, d–h, · 200; c, · 100.
involved in mediating alveolar bone
loss (see below for discussion). Thus,
inhibition of OPG-L via OPG signifi-
cantly decreases alveolar bone destruc-
tion and local bone resorption in Aa-
HuPBL-NOD/SCID mice. Moreover,
whereas the number of osteoclasts was
significantly increased in HuPBL-
NOD/SCID mice in response to
microbial infection, only a few TRAP+
osteoclasts could be detected in Aa-
HuPBL-NOD/SCID mice treated with
OPG (Table 1). These results indicate
that the alveolar bone destruction
observed in periodontitis is due at
least in part to the action of osteo-
clasts activated by OPG-L. Interesting-
ly, inhibition of OPG-L activity via
OPG had no obvious effect on the
severity of periodontal inflammation
itself (Figure 3, g and h), consistent
with our previous findings in the rat
arthritis model (31) and in the colla-
gen-induced arthritis model (40). This
observation implies that tissue inflam-
mation and alveolar bone destruction
are relatively independent aspects of
periodontal infections. In summary,
our functional data show that A. actin-
omycetemcomitans activates CD4+ T
cells in the periodontium and induces
them to express OPG-L, and that
OPG-L is a key mediator of alveolar
bone destruction in microorganism-
induced periodontal infection.
Discussion
Periodontitis, a prime cause of tooth
loss in humans, results from the
interplay between specific bacterial
infections and host immune respons-
es. Human periodontitis is character-
ized by prominent inflammatory
infiltrates and is associated with irre-
versible loss of alveolar bone and/or
connective tissue attachment in the
periodontium. We generated HuPBL-
NOD/SCID mice, using human
leukocytes from LJP patients trans-
planted into NOD/SCID mice (24),
to elucidate the mechanisms by
which antimicrobial host immune
responses contribute to alveolar bone
destruction. Oral challenge of
HuPBL-NOD/SCID mice with A.
actinomycetemcomitans produced a
microorganism-specific human peri-
odontal infection in a “humanized”
mouse model.
Perturbation of the T-cell immune
repertoire is often observed in chronic
inflammatory diseases such as
rheumatoid arthritis (41–42). Recent-
ly, we have shown using a rat model of
arthritis that activated T cells partici-
pate in regulating bone loss and joint
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Figure 4
(a–d) A. actinomycetemcomitans stimulates
OPG-L expression on periodontal CD4+ T
cells. (a) Unstimulated HuPBL-derived CD4+
T cells stained with OPG-FITC; negative con-
trol. (b) HuPBL-derived CD4+ T cells restim-
ulated with anti-TCR plus CD28 mAb’s, fol-
lowed by staining with isotypic control Ab;
background control. (c) HuPBL-derived
CD4+ T cells restimulated with anti-TCR
plus CD28 mAb’s, followed by staining with
OPG-FITC; positive control. (d) Periodontal
CD4+ T cells derived from Aa-HuPBL-
NOD/SCID mice stimulated with A. actino-
mycetemcomitans sonicate antigens, followed
by staining with OPG-FITC. Periodontal
CD4+ T cells restimulated with P. gingivalis
sonicate antigens did not induce significant
membrane OPG-L expression over the back-
ground level (data not shown). OPG-L
membrane expression was determined by
FACS analyses 48 hours later. (e) Reduction
of alveolar bone destruction in OPG-Fc
treated Aa-HuPBL-NOD/SCID mice. Groups
of mice as indicated were infected with A.
actinomycetemcomitans followed by in vivo
treatment with soluble human OPG-Fc
fusion protein. Alveolar bone loss (mean
values ± SD) was assessed at 8 weeks and
normalized to the positive control, Aa-
infected BALB/c mice (100%). Group I,
sham-infected NOD/SCID mice (n = 10);
group II, Aa-infected HuPBL-NOD/SCID
mice not injected with OPG-Fc (n = 16);
group III, Aa-infected HuPBL-NOD/SCID
mice injected with OPG-Fc (n = 10); group
IV, Aa-infected HuPBL-NOD/SCID mice
injected with PBS (n = 8). AThe differences in
alveolar bone loss between group III and
groups II and IV are statistically significant
(P < 0.002).
destruction through their expression
of OPG-L, a key mediator of osteoclas-
togenesis and osteoclast activation
(31). While T cells are probably not
required for normal bone homeostasis
(27, 29–30), we proposed that local or
systemic pathology within an osseous
environment due to microbial or viral
infections, autoimmune conditions
(31), tumorigenesis or metastasis (43),
or injuries could attract T cells capable
of contributing to bone remodeling
through the production of OPG-L.
Our results show that the oral
microorganism A. actinomycetemcomi-
tans can activate OPG-L production in
CD4+ T cells, and they provide, albeit
indirectly, the first evidence that envi-
ronmental pathogens regulate expres-
sion of OPG-L on pathogen-specific T
cells. Recently, OPG-L–independent
triggering of osteoclast differentiation
has been reported (44), a finding con-
sistent with our observation that injec-
tion of soluble OPG (for 4 weeks) did
not completely block alveolar bone
destruction in vivo (approximately
75%; Figure 4e). It must be acknowl-
edged that there are auxiliary factors
of potential importance in the model
we describe. Thus it is known that the
expression of proinflammatory
cytokines (e.g., IL-1 and TNF- a ) can
also regulate the relative balance of
OPG-L and OPG (osteoclastogenesis
inhibitory factor) in the bone microen-
vironment and/or mesenchymal tis-
sues adjacent to bone (45–46), thus
contributing to bone destruction inde-
pendently of cell-mediated immunity.
Additionally, the potential contribu-
tion of local mucosal cells, dental cells,
and/or phagocytes (e.g., mono-
cytes/macrophages, etc.; refs. 47, 48) in
the early stages of infection or inflam-
mation has yet to be defined, either in
this model or in human periodontitis.
Thus while our data suggest that
microorganism-activated CD4+ T cells
are implicated as an important feature
of alveolar bone loss in our model sys-
tem, they do not prove unequivocally
that OPG-L produced by those CD4+ T
cells is responsible for the increased
alveolar bone destruction seen. Selec-
tive depletion of such cells prior to
adoptive transfer would address this
question but has not yet proven to be
technically feasible. Nevertheless, it is
likely that CD4+ T cells of LJP patients
differ fundamentally (in phenotype
and/or genotype) from those of nor-
mal healthy subjects (49). This possi-
bility is supported by our recent sepa-
rate study, in which CD4+ T cells
isolated from Aa-N-HuPBL-
NOD/SCID mice (using HuPBL from
normal healthy subjects; Figure 1b:
group V) showed significantly less
OPG-L expression by FACS analysis
(data not shown). However, the under-
lying mechanism(s) for any differences
awaits further investigation.
In summary, our results show that
CD4+ T cell–mediated immunity is
involved in the modulation of peri-
odontal bone destruction in HuPBL-
NOD/SCID mice after oral inocula-
tion of A. actinomycetemcomitans. In
vivo and in vitro A. actinomycetem-
comitans stimulation results in the
activation of CD4+ T cells and upreg-
ulation of OPG-L. Inhibition of OPG-
L function via the decoy receptor
OPG significantly reduces alveolar
bone destruction in HuPBL-
NOD/SCID mice in response to oral
microbial infections. Moreover, OPG
treatment significantly reduces the
numbers of osteoclasts at the sites of
local periodontal infection. Experi-
ments are currently under way to test
whether the same strategy can be
used to prevent alveolar bone destruc-
tion before the full burst of peri-
odontal inflammation and immune
activation is established. Our results
suggest a critical role for human
CD4+ T cells reactive to oral microor-
ganisms in periodontal disease.
Microbial induction of OPG-L
expression on T cells and OPG-
L–mediated osteoclast activation and
bone loss thus can provide a molecu-
lar explanation for the alveolar bone
destruction observed in local peri-
odontal infections. Inhibition of the
function of OPG-L may thus have
therapeutic value to prevent or to
interrupt alveolar bone and/or tooth
loss in human periodontal disease.
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